Log in

TELA TELA Bio, Inc. NASDAQ · United States

TELA Bio (TELA) news

Latest TELA Bio news

We have not published a story on TELA Bio yet. When there is news, it will appear here.

TELA Bio annual financials

LineFY2025FY2024
Revenue$80.3 million$69.3 million
Research and development$9.2 million$8.8 million
Net income (loss)-$38.8 million-$37.8 million
Cash from operations-$28.2 million-$41.6 million
Cash and equivalents$50.8 million$52.7 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $30.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about TELA Bio

What is the ticker symbol of TELA Bio?

TELA Bio, Inc. trades under the ticker TELA on NASDAQ.

Where is TELA Bio listed?

TELA Bio, Inc. is listed on NASDAQ.

Which country or territory is TELA Bio listed under?

Our directory records TELA Bio, Inc. under United States.

Does aibio.space cover TELA Bio?

aibio.space lists TELA Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was TELA Bio's revenue last year?

$80.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is TELA Bio profitable?

TELA Bio, Inc. reported a net loss of $38.8 million for the fiscal year ended Dec 31, 2025, and used $28.2 million of cash in operations, per its annual report to the SEC.

How much does TELA Bio spend on research and development?

$9.2 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does TELA Bio have?

$30.4 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest TELA Bio (TELA) stock news?

Our latest story on TELA Bio, dated Sep 28, 2026: "TELA Bio gets lender consent to pause revenue covenant test". The consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent. Source.

Does TELA Bio have debt, a term loan or convertible notes?

Our latest debt story, dated Sep 28, 2026: "TELA Bio gets lender consent to pause revenue covenant test". The consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent. Source.

How can I follow TELA Bio (TELA) news?

Press Follow on this page to add TELA Bio to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming TELA Bio so far, in Debt Financing.

Investor discussion: TELA Bio

Members talk about TELA Bio (TELA). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TELA Bio, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  2. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  3. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  4. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  5. Distress

    Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01,9.01). Source

  6. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TELA on TradingView.

Listing details

TELA Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TELA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
TELA Bio, Inc.
Ticker
TELA
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.